We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Non-Invasive Skin Biopsy Test Allows Clinicians to Look inside Nerves for Diagnosing Neurodegenerative Disorders

By LabMedica International staff writers
Posted on 24 Mar 2023

The diagnosis of neurodegenerative disorders such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy can pose significant challenges for clinicians. More...

According to scientific studies, these disorders are misdiagnosed over 30% of the time, particularly during the early stages of presentation. Over the years, researchers have searched for biomarkers in the blood and spinal fluid and employed advanced radiographic methods to image neuron changes in the brain. However, these tests have not been sufficiently sensitive or specific, often failing to detect individuals with the diseases or indicating disease consistency in those who do not have them.

CND Life Sciences (Phoenix, AZ, USA) has developed the first-ever test in the market that can examine the nerves inside the human body and detect the protein accumulation in individuals with synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder. These diseases are characterized by the accumulation of a misfolded protein called alpha-synuclein in the nervous system, which is unique to individuals with synucleinopathies.

The Syn-One Test is a minimally invasive skin biopsy (a punch biopsy with no stitches required) that provides physicians with visual evidence of these proteins accumulating within a patient’s nerves. Skin punch biopsy is an effective, reliable, non-invasive test for detecting such proteins, and can help find a cure for these neurodegenerative diseases. The reliability and effectiveness of this minimally invasive test have gained the attention of hundreds of clinicians across the US who are now using it as a diagnostic aid for the early detection of these synucleinopathies.

"Syn-One is changing the way clinicians diagnose many of these complex neurodegenerative diseases, and in parallel, biopharmaceutical companies are realizing how important it is to use Syn-One as a biomarker for clinical trials targeting alpha-synuclein," said Todd Levine, MD, CND's Chief Medical Officer and Co-Founder.

Related Links:
CND Life Sciences 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
HPV Test
Allplex HPV28 Detection
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Yourgene Insight DPYD assay enables accurate detection of 19 clinically relevant DPYD variants to support identification of patients at increased risk of severe toxicity from fluoropyrimidine‑based therapy (photo courtesy of Yourgene Health)

DPYD Genotyping Assay Supports Safer Fluoropyrimidine Chemotherapy Dosing

Fluoropyrimidine-based chemotherapy can lead to severe toxicity in patients with specific variants in the dihydropyrimidine dehydrogenase (DPYD) gene, making pre-treatment assessment a critical step in... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.